CINaM - Centre Interdisciplinaire de Nanoscience de Marseille


Logo tutelle


Sur le Web du CNRS

  • CINaM
  • Campus de Luminy
  • Case 913
  • 13288 Marseille Cedex 9
  • Tel : +33(0)4 91 17 28 00
  • Fax : +33(0)4 91 41 89 16

Accueil du site > Séminaires > A venir ...

A venir ...

Jeudi 15 Juin 2017
formerly Head of Medicinal Chemistry Department and Scientific Director (Sanofi) Université Paris Descartes, PRES Sorbonne Paris Cité, Laboratoire de Chimie et Biochimie pharmacologiques et toxicologiques, Paris
Nanotechnologies in general and phosphorus dendrimers in particular to treat cancers. Current situation and opportunities
The main objective of nanomedicine research is the development of nanoparticles as drug delivery systems or drugs per se to fight diseases, such as cancers, which are a leading cause of death within developed nations. Nanotechnology, in particular the nanocarrier approach to drug delivery, has attracted much attention in the development of targeted anticancer therapies aimed at avoiding, for instance, the systemic toxicities of classical small molecule cytotoxic drugs. The nanotherapeutic technologies currently used and proposed for anticancer drug delivery therapies are as follows: polymer-drug conjugates, polymer micelles, liposomes, dendrons, dendrimers, mesoporous silica, albumin nanoparticles, metallic nanoparticles, chitosan nanoparticles etc. Results from pre-clinical and clinical trials using nanoparticles are encouraging, suggesting that nanoparticles provide opportunities to design and tune particular properties of drugs. Such interventions are not possible with other types of therapeutics and have thus fueled much enthusiasm with regards the wealth of opportunities afforded by this emerging field of nanoscience in oncology. The focus of this presentation will be analyzing the current challenges and remaining issues facing this infinite armada in systematic cancer nanotherapy. An important consideration is striking a correct balance between sophistication of nanocarriers to be used in the nanotherapies and their ease of development for example to deliver new molecular entities or to be used as drug per se. Finally, the future of cancer nanomedicine will be presented and analyzed with regards nanoparticles such as original phosphorus metallodendrimers developed in collaboration with Professor J-P. Majoral (LCC, Toulouse, France). Related references: 1) Anticancer copper(II) phosphorus dendrimers are potent proapoptotic Bax activators, Mignani, S.; El Brahmi, N.; Eloy, L.; Poupon, J.; Nicolas,V.; Steinmetz, A.; El Kazzouli,S.; Bousmina, M. M. ; Blanchard-Desce, M. ; CaminadeA-M.; Majoral,J-P.; Cresteil, T. Eur. J. Med. Chem., accepted for publication 2) Dendrimer-based magnetic iron oxide nanoparticles: their synthesis and biomedical applications, Sun, W.J.; Mignani, S; Shen, M.W.; Shi, X.Y. Drug Discovery Today, 2016, 21, 1873-1885 3) Advances in Combination Therapies Based on Nanoparticles for Efficacious Cancer Treatment: An Analytical Report Mignani, S; Bryszewska, M; Klajnert-Maculewicz, B; Zablocka, M; Majoral, JP. Biomacromolecules, 2015, 16, 1-27 4) In vitro PAMAM, phosphorus and viologen-phosphorus dendrimers prevent rotenone-induced cell damage, Milowska, K; Szwed, A; Zablocka, M; Caminade, AM; Majoral, J-P.; Mignani, S ; Gabryelak, T.; Bryszewska, M., International Journal of Pharmaceutics. 2014, 474, 42-49. 5) Original Multivalent Copper(II)-Conjugated Phosphorus Dendrimers and Corresponding Mononuclear Copper(II) Complexes with Antitumoral Activities, El Brahmi, N.; El Kazzouli, S.; Mignani, S.; Essassi, E. ; Aubert, G. ; Laurent, R.; Caminade, A-M.; Bousmina, M .M.; Cresteil, T.; Majoral, J-P. Molecular Pharmaceutics, 2013, 10, 1459-1464.

Jeudi 29 Juin 2017
Juris Purans
Institut de Physique des Solides de Riga, Lettonie

Jeudi 6 Juillet 2017
Centre de Recherche Paul Pascal (CRPP), Bordeaux
Controlled organic syntheses of large polycyclic aromatic compounds, from Scholl to Perkin strategies
The Scholl reaction is a popular tool for bottom-up organic syntheses of large polycyclic aromatic hydrocarbons, or nanographenes, since it allows the formation of numerous carbon-carbon bonds in one step. Nevertheless this well-known reaction remains unpredictable and can sometimes lead to surprising results, such as rearrangements or unexpected regioselectivities that lead to highly twisted helicenic arenes instead of their flat isomers. With the aim to avoid fully apolar hydrocarbons which are often very difficult to purify, we developed a complementary synthetic approach for the formation of large carboxy-substituted polycyclic aromatic compounds. This strategy relies on Perkin reactions for the synthesis of flexible precursors, followed by various cyclization reactions. This new synthetic approach has been optimized and can now be applied to the formation of interesting compounds such as poly-helicenes, columnar liquid crystals or macrocycles, as precursors of short carbon nanotubes.

Jeudi 12 Octobre 2017
Olivier Pouliquen
IUSTI, CNRS - Aix-Marseille Université